- Co-founded by world leading dermatology experts and Medicxi
- Merger of six asset-centric companies to form a new R&D-centric multi-platform pipeline in immuno-dermatology to harness cutting edge-science and technologies
- Vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet need
Boston, Massachusetts and Geneva, Switzerland, 12th February 2024 – Alys Pharmaceuticals, Inc. (“Alys”), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi. Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.